Latest Health News

NRW Holdings capped FY25 with strong financials and a strategic acquisition, setting the stage for an optimistic FY26. The addition of Fredon Industries expands NRW’s footprint and diversifies its service pillars amid challenging market conditions.

PeopleIN Limited is set to divest its majority stake in Techforce Personnel, securing over a 100% return and strengthening its balance sheet to fuel future acquisitions.

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.

HeraMED has secured a pilot agreement with Lee Health, a leading US non-profit health system, to trial its HeraCARE digital maternity platform, aiming to transform prenatal and postpartum care through remote monitoring and virtual engagement.

New Zealand King Salmon reported an FY25 net loss driven by a shortened reporting period and biological challenges, while advancing its Blue Endeavour pilot project despite delays. The company projects a cautious recovery in FY26 with EBITDA guidance between NZD 9 million and 15 million.

New Zealand King Salmon reports a $6.3 million net loss for an eight-month FY25 period, reflecting operational challenges and a shortened reporting cycle, while outlining cautious optimism for FY26 with targeted growth investments.

Adherium Limited has reached a pivotal commercial milestone by expanding its Remote Patient Monitoring program across 110 U.S. Allergy Partners clinics, activating nearly 70% of the network and onboarding close to 700 patients in six months.

Anatara Lifesciences has completed the final tranche of its placement, issuing over 66 million shares and granting options to its lead manager, marking a key step in its capital raising strategy.

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.

Race Oncology has received ethics approval to launch its HARNESS-1 Phase 1a/b trial testing RC220 combined with osimertinib in EGFR-mutated non-small cell lung cancer patients, marking a key step toward addressing resistance to current therapies.